IMTX Immatics
- 12.130
- +1.100+9.97%
- 12.590
- +0.460+3.79%
Immatics News
Mizuho Bank: Maintaining the Immatics (IMTX.US) rating, adjusted from buy to buy rating, and adjusted the target price from $14.00 to $16.00.
Immatics Analyst Ratings
Mizuho Maintains Buy on Immatics, Raises Price Target to $16
Buy Rating Affirmed for Immatics on Strong TCR-T Cell Therapy Data and Promising Outlook
Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
Buy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic Partnerships
Positive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh's Recommendation
Immatics: Strong Buy Rating Supported by Promising Clinical Results and Upcoming Catalysts
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cormedix (CRMD), Immatics (IMTX) and Johnson & Johnson (JNJ)
Positive Clinical Phase 1b Results and Robust Financial Position Boost Immatics (IMTX) to a 'Buy' Rating
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Immatics (IMTX)
Immatics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Ovid Therapeutics (OVID), Lantheus (LNTH) and Immatics (IMTX)
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Omega Therapeutics (OMGA) and Roivant Sciences (ROIV)
Immatics (IMTX) Receives a Buy From Mizuho Securities
Mizuho Ups Price Target on Immatics to $14 From $12, Maintains Buy Rating
Mizuho Securities Keeps Their Buy Rating on Immatics (IMTX)
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), CVS Health (CVS)
Analysis
Price Target
No Data
